Cargando…
Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype
INTRODUCTION: Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40–80%. LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations (small-cell lung carcinoma (SCLC...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933830/ https://www.ncbi.nlm.nih.gov/pubmed/31751303 http://dx.doi.org/10.1530/EC-19-0372 |
_version_ | 1783483289335496704 |
---|---|
author | Hermans, B C M Derks, J L Groen, H J M Stigt, J A van Suylen, R J Hillen, L M van den Broek, E C Speel, E J M Dingemans, A-M C |
author_facet | Hermans, B C M Derks, J L Groen, H J M Stigt, J A van Suylen, R J Hillen, L M van den Broek, E C Speel, E J M Dingemans, A-M C |
author_sort | Hermans, B C M |
collection | PubMed |
description | INTRODUCTION: Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40–80%. LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations (small-cell lung carcinoma (SCLC)-like), the second with mutations in TP53 and STK11/KEAP1 (non-small-cell lung carcinoma (NSCLC)-like). Here we evaluated 11 LCNEC patients with only a solitary brain metastasis and evaluate phenotype, genotype and follow-up. METHODS: Eleven LCNEC patients with solitary brain metastases were analyzed. Clinical characteristics and survival data were retrieved from medical records. Pathological analysis included histomorphological analysis, immunohistochemistry (pRB and Ki-67 PI) and next-generation sequencing (TP53, RB1, STK11, KEAP1 and MEN1). RESULTS: All patients had N0 or N1 disease. Median overall survival (OS) was 12 months (95% confidence interval (CI) 5.5–18.5 months). Mean Ki-67 PI was 59% (range 15–100%). In 6/11 LCNEC Ki-67 PI was ≤40%. OS was longer for Ki-67 ≤40% compared to >40% (17 months (95% CI 11–23 months) vs 5 months (95% CI 0.7–9 months), P = 0.007). Two patients were still alive at follow-up after 86 and 103 months, both had Ki-67 ≤40%. 8/11 patients could be subclassified, and both SCLC-like (n = 6) and NSCLC-like (n = 2) subtypes were present. No MEN1 mutation was found. CONCLUSION: Stage IV LCNEC with a solitary brain metastasis and N0/N1 disease show in the majority of cases Ki-67 PI ≤40% and prolonged survival, distinguishing them from general LCNEC. This unique subgroup can be both of the SCLC-like and NSCLC-like subtype. |
format | Online Article Text |
id | pubmed-6933830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-69338302019-12-30 Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype Hermans, B C M Derks, J L Groen, H J M Stigt, J A van Suylen, R J Hillen, L M van den Broek, E C Speel, E J M Dingemans, A-M C Endocr Connect Research INTRODUCTION: Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40–80%. LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations (small-cell lung carcinoma (SCLC)-like), the second with mutations in TP53 and STK11/KEAP1 (non-small-cell lung carcinoma (NSCLC)-like). Here we evaluated 11 LCNEC patients with only a solitary brain metastasis and evaluate phenotype, genotype and follow-up. METHODS: Eleven LCNEC patients with solitary brain metastases were analyzed. Clinical characteristics and survival data were retrieved from medical records. Pathological analysis included histomorphological analysis, immunohistochemistry (pRB and Ki-67 PI) and next-generation sequencing (TP53, RB1, STK11, KEAP1 and MEN1). RESULTS: All patients had N0 or N1 disease. Median overall survival (OS) was 12 months (95% confidence interval (CI) 5.5–18.5 months). Mean Ki-67 PI was 59% (range 15–100%). In 6/11 LCNEC Ki-67 PI was ≤40%. OS was longer for Ki-67 ≤40% compared to >40% (17 months (95% CI 11–23 months) vs 5 months (95% CI 0.7–9 months), P = 0.007). Two patients were still alive at follow-up after 86 and 103 months, both had Ki-67 ≤40%. 8/11 patients could be subclassified, and both SCLC-like (n = 6) and NSCLC-like (n = 2) subtypes were present. No MEN1 mutation was found. CONCLUSION: Stage IV LCNEC with a solitary brain metastasis and N0/N1 disease show in the majority of cases Ki-67 PI ≤40% and prolonged survival, distinguishing them from general LCNEC. This unique subgroup can be both of the SCLC-like and NSCLC-like subtype. Bioscientifica Ltd 2019-11-14 /pmc/articles/PMC6933830/ /pubmed/31751303 http://dx.doi.org/10.1530/EC-19-0372 Text en © 2019 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Research Hermans, B C M Derks, J L Groen, H J M Stigt, J A van Suylen, R J Hillen, L M van den Broek, E C Speel, E J M Dingemans, A-M C Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype |
title | Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype |
title_full | Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype |
title_fullStr | Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype |
title_full_unstemmed | Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype |
title_short | Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype |
title_sort | large cell neuroendocrine carcinoma with a solitary brain metastasis and low ki-67: a unique subtype |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933830/ https://www.ncbi.nlm.nih.gov/pubmed/31751303 http://dx.doi.org/10.1530/EC-19-0372 |
work_keys_str_mv | AT hermansbcm largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT derksjl largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT groenhjm largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT stigtja largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT vansuylenrj largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT hillenlm largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT vandenbroekec largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT speelejm largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT dingemansamc largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype |